|
Market Closed -
Nasdaq
23:00:00 23/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 62.34 USD | -5.49% |
|
-7.77% | -17.93% |
Company Valuation: PTC Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,816 | 2,786 | 2,080 | 3,481 | 6,099 | 5,203 | - | - |
| Change | - | -1.06% | -25.35% | 67.4% | 75.18% | -14.69% | - | - |
| Enterprise Value (EV) 1 | 2,474 | 2,947 | 1,487 | 2,627 | 4,440 | 3,332 | 3,058 | 3,332 |
| Change | - | 19.12% | -49.54% | 76.65% | 69% | -24.96% | -8.23% | 8.98% |
| P/E | -5.36x | -4.9x | -3.29x | -9.54x | 9.76x | 40x | 21.8x | 16.5x |
| PBR | 1,952x | -7.89x | -2.55x | -3.19x | -30.1x | -46.2x | 30.6x | 8.29x |
| PEG | - | -1.01x | -0.44x | 0.2x | -0x | -0.5x | 0.3x | 0.5x |
| Capitalization / Revenue | 5.23x | 3.99x | 2.22x | 4.32x | 3.52x | 4.14x | 3.78x | 3.25x |
| EV / Revenue | 4.59x | 4.22x | 1.59x | 3.26x | 2.57x | 2.65x | 2.22x | 2.08x |
| EV / EBITDA | -7.97x | -9.25x | -7.33x | -11.6x | 4.9x | 8.09x | 5.62x | 4.83x |
| EV / EBIT | -6.61x | -6.59x | -3.38x | -8.68x | 5.12x | 9.42x | 6.44x | 5.5x |
| EV / FCF | -8.85x | -7.58x | -7.96x | -23x | 6.32x | -256x | 49.3x | 15.1x |
| FCF Yield | -11.3% | -13.2% | -12.6% | -4.35% | 15.8% | -0.39% | 2.03% | 6.62% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 | 1.557 | 2.857 | 3.788 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 538.6 | 698.8 | 937.8 | 806.8 | 1,731 | 1,258 | 1,377 | 1,602 |
| EBITDA 1 | -310.3 | -318.6 | -202.9 | -226.9 | 905.8 | 411.6 | 544.5 | 689.3 |
| EBIT 1 | -374.4 | -447.4 | -439.5 | -302.6 | 866.9 | 353.7 | 474.8 | 605.6 |
| Net income 1 | -523.9 | -559 | -626.6 | -363.3 | 682.6 | 145.4 | 231.5 | 344.6 |
| Net Debt 1 | -341.9 | 161 | -592.5 | -854.3 | -1,659 | -1,871 | -2,145 | -1,871 |
| Reference price 2 | 39.83 | 38.17 | 27.56 | 45.14 | 75.96 | 62.34 | 62.34 | 62.34 |
| Nbr of stocks (in thousands) | 70,698 | 72,991 | 75,463 | 77,125 | 80,288 | 83,461 | - | - |
| Announcement Date | 2/22/22 A | 2/21/23 A | 2/29/24 A | 2/27/25 A | 2/19/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 42.36x | 2.89x | 8.83x | -.--% | 5.2B | |
| 33.27x | 12.06x | 24.51x | 0.59% | 1,026B | |
| 29.94x | 6.66x | 18.64x | 2% | 649B | |
| 33.54x | 7.85x | 16.21x | 2.59% | 468B | |
| 19.72x | 4.82x | 11.95x | 2.75% | 352B | |
| 20.01x | 5.21x | 12.94x | 3.07% | 271B | |
| 21.55x | 4.46x | 12.7x | 1.98% | 256B | |
| 26.04x | 6.76x | 12.04x | 2.46% | 220B | |
| -46.18x | 6.71x | 26.22x | 2.16% | 188B | |
| 11.59x | 4.21x | 8.76x | 4.34% | 170B | |
| Average | 19.18x | 6.16x | 15.28x | 2.19% | 360.43B | |
| Weighted average by Cap. | 23.97x | 7.80x | 18.01x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- PTCT Stock
- Valuation PTC Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
